news & events
ysios news
02.04.19
Aura Biosciences Completes $40 Million Series D Financing
26.10.18
Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development
26.09.18
Minoryx Therapeutics raises €21.3M in Series B funding round
24.09.18
Ysios Capital strengthens its team with the appointment of Guillem Laporta as Principal and two new Venture Partners
16.03.18
Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson’s disease
31.01.18
QIAGEN enters into agreement to acquire STAT-Dx, plans to launch a next-generation, fully integrated multiplex platform for syndromic disease testing
15.11.17
Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs
21.07.17
Kala Pharmaceuticals Announces Pricing of Initial Public Offering
30.06.17
Babyscripts Raises $5.7 Million to Build the Market’s Most Robust, Clinically-Validated Virtual Care Women’s Health Platform
23.05.17
Anaconda Biomed Secures 15 Million Euro in Series A Financing Led by Ysios Capital, Innogest Capital and Omega Funds.
